Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39063
NL-OMON39063
Not yet recruiting
Not Applicable

ONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY) - Response to interferon in hepatitis B: relation to IL28b and Apo E

Academisch Medisch Centrum0 sites135 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionschronic hepatitis Bliver inflammation1001965410047438

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic hepatitis B
Sponsor
Academisch Medisch Centrum
Enrollment
135
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •chronic hepatitis B
  • •treated with interferon

Exclusion Criteria

  • •coinfections with HIV, HCV

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
ong-term follow-up of patients with extrahepatic biliary atresie and Kasai hepatoportoenterostomy: assessment of abnormalities on MR imaging and implications for follow-up.congenital biliary atresiaKasai portoenterostomy10019654
NL-OMON30396Erasmus MC, Universitair Medisch Centrum Rotterdam16
Not yet recruiting
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis B
ACTRN12614000628640Gilead Sciences, Inc.150
Active, not recruiting
Phase 1
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94
Active, not recruiting
Phase 1
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-002245-11-GBbluebird bio, Inc.94
Active, not recruiting
Phase 1
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-002245-11-DEbluebird bio, Inc.94